Medical management of Spinal TB Pearls & pitfalls

Courtesy: Abhay Nene, Ashok Shyam, IORG, OrthoTV

Topic / Overview

Comprehensive principles governing modern non-surgical and medical management of spinal tuberculosis (TB). The presentation addresses the shifting paradigm from surgical decompression to conservative chemotherapy, diagnostic modalities and their pitfalls, evidence-based anti-tubercular therapy (AKT/ATT) protocols, drug resistance patterns, and disease monitoring.

Background / Problems

• Changing Landscape of Spinal Surgery: Surgical intervention rates for spinal TB have declined dramatically due to highly efficacious medical regimens.

• Evolution of the Middle Path Regimen (Tuli): Originally restricted to early disease diagnosed promptly. Today, the scope of conservative medical therapy has widened significantly, fulfilling Tuli’s prediction that the vast majority of cases resolve non-operatively.

• Transient Instability: Spinal instability and severe pain (even inability to turn in bed) are transient; with appropriate chemotherapy, lesions consolidate, stabilize, and heal without necessitating operative fusion.

• Iatrogenic Drug Resistance: The speaker emphasizes that the leading cause of multi-drug resistant TB (MDR-TB) is poorly prescribed, underdosed, fixed-dose combination (FDC) regimens initiated by orthopedic surgeons.

• Medicolegal Vulnerability: Relying purely on clinicoradiological diagnosis without tissue confirmation has resulted in litigation against senior spine specialists (e.g., empirical AKT initiated for missed lymphoma).

Diagnostic Workup, Modalities, and Pitfalls

1. Advanced Molecular and Microbiological Assays

• Histopathology & Smear: Send tissue samples for histopathology, Acid-Fast Bacilli (AFB) smear, and molecular tests.

• GeneXpert (CBNAAT) vs. GeneXpert Ultra:

  • GeneXpert Ultra: 16 times more sensitive than standard GeneXpert and widely available.

  • Negative GeneXpert: Does not rule out TB.

  • Positive GeneXpert: Does not definitively confirm active, viable infection. In patients with prior spinal TB, a positive result may represent non-viable DNA contamination or residual debris.

  • Rifampicin Resistance Misinterpretation: When cycle thresholds are very low, rifampicin resistance can be falsely reported, leading to an incorrect diagnosis of MDR-TB.

• Line Probe Assay (LPA):

  • LPA 2: Positive even in smear-negative specimens; more economical than GeneXpert.

  • Indication: Send for first-line and second-line LPA in treatment-naive patients where Mycobacterium tuberculosis (MTB) is identified.

  • Limitation: Frequently negative or unyielding once the patient has already initiated AKT.

• Pyrosequencing: Recommended for patients already on AKT who require rapid drug-resistance profiling beyond standard LPA.

• Culture: Remains the indispensable gold standard despite modern rapid molecular panels.

2. Biopsy Technique

• Modality: CT-guided core biopsy is strictly superior to Fine Needle Aspiration Cytology (FNAC).

• Sample Volume: It is essential to send three separate samples for microbiology, histology, and molecular testing.

• Empirical Treatment Caution: If practicing in a resource-limited setting without biopsy access, the treating surgeon must document and explicitly inform the patient that therapy is empirical due to the lack of biopsy verification.

3. Imaging Limitations

• MRI Non-Specificity: Many atypical presentations on MRI represent spinal TB, while classic-appearing lesions frequently turn out to be non-tubercular entities (such as lymphoma or pyogenic spondylodiscitis).

• PET Scan Pitfall (Speaker’s Strong Opinion): PET scans reflect metabolic activity/inflammation rather than active bacterial proliferation. A positive PET scan does not distinguish active infection from resolving inflammation or malignancy. The speaker labels the claim from northern Indian studies advocating a negative PET scan as an endpoint for stopping AKT as unfounded and unsupported by evidence.

Indications / Patient Selection for Medical Management

The scope of primary medical management has expanded to encompass presentations previously considered absolute surgical indications:

• Radiological Cord Compression with Upper Motor Neuron Signs: Brisk reflexes and radiological cord compression on presentation do not automatically mandate surgery; a consecutive series of 50 patients with documented cord compression was successfully managed conservatively.

• Extensive Posterior Element Involvement: Massive posterior element disease can resolve completely with targeted chemotherapy.

• Severe Deformity / Bony Destruction: Operating anteriorly in extensive destruction frequently results in implant collapse and complications; conservative chemotherapy yields superior, safer consolidation.

Technique / Medical Regimens and Principles

1. Standard Chemotherapy Protocol

• Intensive Phase: 2 months of EHRZ (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide).

• Continuation Phase: 12 months of HRE (Isoniazid, Rifampicin, Ethambutol).

  • Rationale for Ethambutol in Continuation: Approximately 16% of the Indian population harbors primary/inherent INH resistance. Omitting Ethambutol (prescribing HR alone) risks generating acquired rifampicin resistance (MDR-TB). Ethambutol must be continued unless baseline culture confirms INH sensitivity.

• Role of Streptomycin: No added clinical benefit; the concept that streptomycin achieves superior bony penetration is false.

• Vitamin D Supplementation: Mandatory adjunct. Innate antimycobacterial immunity is vitamin D-dependent (explaining historical therapeutic responses in sanatoria).

2. Administration Rules and Weight-Based Dosing

• Administration: Must be taken first thing in the morning on an empty stomach; no food intake for 1 hour post-dose to ensure adequate bioavailability.

• Patient Counseling: Warn patients that urine and secretions will turn orange/reddish to prevent self-discontinuation.

• Weight-Based Dosing: Prescribe precise mg/kg doses rather than arbitrary FDC blister packs. Beware of maximum ceiling doses in obese individuals (e.g., 120–130 kg).

• Cross-Specialty Referral: Due to complex weight calculations and organ toxicity monitoring, the speaker advises that medical dosing and toxicity oversight be delegated to a chest physician/pulmonologist.

3. Managing INH Resistance

• Check LPA results: If the resistance mutation allows, high-dose INH can be utilized to spare the patient an extensive second-line MDR regimen.

• If high-dose INH is not viable, substitute a fluoroquinolone (typically Levofloxacin) for an extended duration.

Drug Resistance: Scope and Demographics

• Primary Resistance in Pediatrics: Approximately 20% of primary pediatric TB cases present with baseline drug resistance.

• Spinal Extra-Pulmonary Paradigm: The historical belief that extra-pulmonary spinal TB rarely exhibits MDR no longer holds; high rates of acquired resistance and primary XDR-TB are actively documented in urban spine practices.

Treatment Monitoring and Evaluation of Failure

Hierarchy of Monitoring Parameters

1. Clinical Response (Primary Determinant): Symptom resolution, weight gain, pain relief, and functional recovery override imaging appearances.

2. Radiological Response (Secondary Determinant):

   • The 3-Month Lag: MRI appearances frequently worsen or show reactive inflammation during the first 3 months despite clinical recovery. Treatment must not be altered based solely on early MRI deterioration.

   • Sterile Collections: Residual high-signal fluid on T2 MRI at 6 to 12 months often represents sterile collections or resolving inflammatory tissue rather than active pus.

3. Inflammatory Markers (Tertiary Determinant): ESR/CRP serve as secondary adjuncts without definitive standalone cutoffs.

Pitfalls in Non-Responders

• Adding a Single Drug: Never add a single new agent (e.g., ciprofloxacin/fluoroquinolones) to a failing or underdosed regimen, as this drives secondary drug resistance.

• Short-Course Chemotherapy: Papers advocating 3-month AKT regimens achieve early bacterial clearance but lead to unacceptably high relapse rates; prolonged therapy is necessary to eradicate persisters and prevent recurrence.

• Second-Line Regimens: Second-line drugs (e.g., Bedaquiline, Delamanid) are stringently regulated. When indicated, empirical regimens require 5 new drugs, continued for a minimum of 5 months after culture conversion. Management of failing regimens must be transferred to a chest physician.

Practical Clinical Implications

• Avoid diagnosing spinal TB on MRI alone; obtain CT-guided tissue for histopathology, AFB, culture, and GeneXpert Ultra before starting treatment.

• Maintain Ethambutol in the continuation phase (HRE) for 12 months to protect against rifampicin resistance driven by occult INH resistance (prevalent in ~16% of the population).

• Never switch or add single agents if a patient fails to improve at 3 months; re-biopsy the lesion, verify compliance and weight-adjusted dosing, and involve a pulmonologist for regulated second-line regimens.

Key Take-Home Points

• Surgical Scope: Radiologically severe cord compression and marked mechanical instability routinely heal under supervised medical treatment; surgery is rarely required.

• Diagnostics: GeneXpert Ultra is 16 times more sensitive than GeneXpert; CT-guided biopsy (3 samples) is mandatory; PET scans detect non-specific metabolic activity and should not be used as an endpoint for stopping AKT.

• Standard Regimen: 2 months of EHRZ followed by 12 months of HRE (not HR); omit streptomycin; routinely supplement vitamin D.

• Response Monitoring: Clinical recovery is the primary guide; MRI often appears worse at 3 months due to reactive inflammation, and residual T2 fluid collections at 12 months are frequently sterile